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ALTERED EXPRESSION OF P53 AND MDM2 IN SUPERFICIAL BLADDER CANCER.
Julian N. Anthony, Amy Darefsky, and David Esrig. Section of Urology, Department of Surgery,
Yale University, School of Medicine, New Haven, CT.
P53 is a tumor suppressor gene shown to be involved in regulation of the cell-cycle.
Alterations in the expression and function of p53 have been implicated in a number of human
malignancies. Recently a cellular protein, mdm2, has been found to have the ability to bind
wild-type p53 and inactivate its function. The purpose of this study was to analyze the
frequency of alterations in the tumor markers p53 and mdm2 for superficial bladder cancer.
Patient data was compiled from clinical charts of 84 patients at Yale-New Haven and West
Haven Veterans Hospitals who underwent transurethral resection for suspected bladder tumors.
Tumor specimens were reviewed and the most representative sections were selected for
immunohistochemical staining with monoclonal antibodies specific to the p53 and mdm2
proteins. The p53 and mdm2 status was then analyzed in relation to probability of recurrence.
P53 nuclear reactivity was detected in 41 of 66 bladder tumors. Mdm2 nuclear reactivity was
detected in 8 of 66 bladder tumors. Bladder tumors that were negative for p53 and positive for
mdm2 had a rate ratio for tumor recurrence that was 20.02 times that of the reference group (p53
negative, mdm2 negative) (p=0.01). Tumors that were positive for p53 and negative for mdm2
had a rate ratio for tumor recurrence that was 3.25 times that of the reference group (p=0.02).
Tumors that were positive for p53 and positive for mdm2 had a rate ratio for tumor recurrence
that was 4.00 times that of the reference group (p=0.05). Any aberration in the tumor markers
p53 and mdm2 have a rate ratio of tumor recurrence 3.31 times that of the reference group
(p=0.01). The expression of mdm2 may function to inactivate wild-type p53 and contribute to
tumorigenesis in superficial bladder cancer.
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Introduction

Bladder cancer is the fifth most common cancer in the United States and the
second most common cancer of the genitourinary tract with an annual incidence of
approximately 18 cases per 100,000'. Approximately 51,600 new cases are diagnosed
annually with an estimated 9,500 deaths in the United States3. 90% of all bladder
cancers are transitional cell carcinomas8. At initial presentation, approximately 5070% of bladder tumors are of a superficial nature and low grade consisting of stage
Tis (carcinoma in situ) or Ta (confined to the mucosa)-5. The majority of these
patients will have recurrences after transurethral resection of the tumor4,5’6 7. For the
most part, tumors that present with a low grade and superficial in nature remain so
throughout the life of the patient5. However, about 25% of these superficially
presenting tumors go on to progress in grade6. At the time of diagnosis
approximately 28% of bladder tumors have invaded the lamina propria (Tl) and
about 24% have invaded into the muscle wall (>T2)8. Metastasis to regional or
distant sites are found in approximately 15% of cases8.
Staging of bladder cancer is dependent upon the depth of invasion. Tis
tumors are confined to the mucosal layer. They are described as flat, nonpapillary,
high grade, anaplastic epithelium which lacks the normal cellular polarity and whose
cells are large and have prominent nucleoli8. Ta tumors are confined to the mucosal
layer of the urothelium. They are papillary in nature and histologically consist of low
grade tumors. Tl tumors extend into the lamina propria of the urothelium. T2
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tumors extend into the superficial muscularis propria. T3a tumors extend into the
deep muscularis propria. T3b tumors extend into the perivesical fat or peritoneum
while T4 tumors extend to contiguous organs such as the prostate or vagina.
Grading of bladder cancer is dependent on a number of histological
characteristics. Features such as cell and nuclear size, nuclear-cytoplasmic ratio,
nuclear pleomorphism and irregularity, hyperchromasia, chromatin clumping, nuclear
crowding and overlapping, prominent nucleoli, and mitotic figures are used to
determine grade9. The degree of change in these criteria dictate the grade of the
tumor ranging from grade one through four.
Recurrence and progression of disease are two important factors in the natural
history of bladder cancer8. Traditionally criteria such as tumor grade, stage, size,
lymphatic invasion, presence of carcinoma in situ, papillary or solid tumor
configuration, multifocal tumors, frequency of tumor recurrences and the patient’s
age have been used in an attempt to predict patterns of recurrence and progression3.
Bladder tumors confined to the mucosa (Stage Ta) have been shown to have a
progression rate of about 3%, those invading the lamina propria (Tl) about 25%-33%,
and those invading the musculature (>T2) about a 50% rate of progression and
metastasis9. Tumors with evidence of CIS have a rate of progression and metastasis
of about 80%81. A current challenge in the treatment of bladder cancer has been to
develop biological markers which would better predict disease progression. An
accurate biological marker could have a profound effect on current treatment
modalities. For example, aggressive therapy could be targeted towards patients
more likely to have disease progression.
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Tumorigenesis is thought to result from a cell’s inability to control
proliferation and disorders in the interactions between cells and their surroundings10.
Oncogenes can cause the formation of tumors when expressed in a cell. They can be
activated by a number of genetic processes including mutation, amplification, or
rearrangement. Oncogenes are able to manifest their cellular affects through several
mechanisms. They can reduce a cells ability to suppress growth and respond to
growth control signals through growth factors and receptors involved with signal
transduction pathways. Oncogenes may also code for transcription factors which
regulate the expression of genes involved in control of the cell cycle' ’.
Tumor suppressor genes (TSGs) can inhibit a tumor cell’s ability to grow.
Tumor suppressor genes act in a recessive manner in that both alleles must be lost or
inactivated in order to lose growth inhibition. However, some tumor suppressor
genes may appear to behave in a dominant fashion like an oncogene. This usually
results from one allele being constitutionally deleted or an abnormal gene product
interfering with the function of the normal one. For example in the hereditary form
of retinoblastoma, the offspring inherits one abnormal gene. A subsequent somatic
mutation to the remaining normal allele results in cancer2”5.
Theories regarding the precise mechanisms of action of TSGs are constantly
evolving based on continually expanding experimental data. TSG products may
bind and inactivate transcription factors which activate genes involved in the
progression of the cell cycle. Conversely, TSGs may code for transcription factors
which activate genes involved in inhibition of the cell cycle'.
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A number of TSGs have been identified which may play a role in the
development and progression of bladder cancer. The retinoblastoma (RB)
susceptibility gene codes for a 110 kD nuclear phosphoprotein thought to be
involved in regulation of the cell cycle. A number of independent investigators have
shown that alterations in the expression of the RB protein may be associated with
more aggressive muscle-invasive bladder tumors and may be a prognostic indicator of
tumor progression6"'67.
Several oncogenes also exist which are thought to play a role in the
development and progression of bladder cancer. Epidermal growth factor (EGF) is a
protein mitogen that is excreted in urine in high concentrations in a biologically
active form68. EGF most likely initiates its tumorigenic effects through binding with
its receptor (EGF-R) and subsequent growth stimulation6970 and induction of
ornithine decarboxylase activity69. Messing has shown there to be an increased
concentration of receptors in premalignant and malignant urothelium71. Both Berger
et al., and Wright et ah, have shown that the overexpression of EGF-Rs on
urothelium correlates with tumor grade and stage in transitional cell carcinomas of
the bladder'" A The protooncogene c-src is involved in differentiation of the
nervous system74'76 and neoplastic progression of colon carcinomas77,78. A study by
Fanning et ah, correlated expression of the c-src protooncogene with histological
grade of bladder carcinomas and suggested a role for c-src in the differentiation of
urothelial cells79. The ras gene family is involved in a number of different human
malignancies80. The H-ras gene product is a 21 kD cell membrane protein involved
in signal transduction pathways81. A recent report by Ooi et ah, found there to be a
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high frequency of H-ras mutations in transitional cell carcinomas of the bladder8".
Viola et al., found there to be increased expression of the H-ras gene product, p21, in
high grade tumors and in premalignant lesions thus suggesting that overexpression
of p21 may be a prognostic indicator in transitional cell carcinoma of the bladder83.
There is a plethora of experimental data implicating p53 as a TSG. When the
wild-type p53 gene is cotransfected into primary rat embryo fibroblasts with
activated oncogenes the transformation frequency is decreased"3,26. Additionally,
studies by Chen et al. demonstrated a decrease in the tumorigenic potential of
transformed cells with the addition of p53 cDNA27. Abnormalities of the p53 gene
have been observed within a broad spectrum of human malignancies involving lung,
breast, stomach, bladder, testis, bone, and colorectum".
The p53 gene is a tumor suppressor gene that has been mapped to human
chromosome 17pl3.1.

Tools of genetic analysis such as cytogenetic and restriction

fragment length protein (RFLP) studies have found aberrations in chromosome 17
associated with human malignancies. Allelic deletions of chromosome 17p have
been found in approximately 60% of tumors involving the colon, breast, lung,
ovaries, cervix, adrenal cortex, and bone and in at least 30% of brain tumors1218. The
p53 gene contains 11 exons and 10 introns. Exons 2-11 code for the actual p53
protein. However, exons 5-9 are evolutionarily highly conserved regions and contain
the majority of genetic mutations. The majority, greater than 95%, of these
mutations are base substitutions and have been localized to four of the five
evolutionarily conserved domains19. It has also been shown that mutations of
specific codons have been associated with different cancer types20,21.
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A number of studies have established a correlation between overexpression of
the p53 protein and prognosis in patients with bladder cancer. Esrig et al., were able
to show that overexpression of p53 in tumor cell nuclei predicts a significantly
increased risk of recurrence and death54. Lipponen found overexpression of p53
protein to be related to progression of stage in bladder cancer. He also found
overexpression of p53 protein to be a significant predictor of survival in papillary and
muscle-invasive bladder tumors55. Sarkis et ah, have a number of studies correlating
overexpression of p53 with prognosis and survival in different stages of bladder
cancer. In one study, they found that T1 bladder cancers that overexpress p53
protein have a higher probability of disease progression and that p53 overexpression
is an important prognostic factor56. Subsequent work by Sarkis et ah, found that
patients with stage Tis disease and p53 nuclear overexpression had a significantly
higher probability for disease progression and death from bladder cancer57. Another
study showed p53 nuclear overexpression to be an independent prognostic indicator
for survival in patients with invasive bladder cancer58.
The p53 protein has been shown to have site specific DNA binding capacity.
It is the central portion of the protein, encoded by the DNA exons with the highest
mutational frequency, that is responsible for this DNA binding activity"2. P53 has
been shown to stimulate and inhibit gene expression most likely through its DNA
binding capacity as a transcriptional factor. Codons 20-42 code for the acidic
activation domain responsible for this activity25. Work by Mack et al. illustrates p53’s
inhibitory effects on gene expression, more specifically on genes with a TATA
promotor region24.
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Maltzman et al. and Kastan et al. demonstrated that increases in cellular
levels of p53 occur after exposure to DNA damaging elements such as UV light,
gamma irradiation, and chemotherapeutic agents'8"9. Kuerbitz et al. were able to
show that these increased levels of p53 resulted in arrest of the cell-cycle at the Gl-S
phase interface^0. P53 is thought to function as the “molecular policeman” of the
genome. P53 induces the cell to arrest prior to the DNA replication of S phase. In
this manner, mutations of the genome are not propagated down further cell lines. If
repair of the damaged DNA is not possible, p53 is thought to induce apoptosis
(programmed cell death)jl

The precise mechanisms of how p53 induces apoptosis

are currently unknown. However, there is genetic evidence indicating how p53
induces arrest of the cell cycle. The wild- type p53-activated fragment (WAF-1)
protein may play a role in p53 induced cell-cycle arrest. The WAF-1 gene is a p53
inducible geneN WAF-1 protein (p21) forms a complex with cyclin-dependent
kinases (CDK’s) and inhibits their activity19. CDK’s are enzymes involved in the
progression of the cell cycle. Therefore, WAF-1 has the ability to arrest the cell
cycle through CDK inactivation.
Recently, molecular genetic studies have allowed for more detailed analysis
of genomic function in addition to the established assessment of genomic integrity.
With improvements in immunohistochemistry (IHC), we are now able to assess
function of the p53 gene at the protein level. Alterations of the p53 gene consist of
point mutations, allelic losses, rearrangements, deletions, and germline mutations"0.
A number of molecular studies have been utilized in the characterization of these
mutations including direct sequencing of PCR amplified DNA fragments and single
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strand conformational polymorphism analysis (SSCP)19.

The sensitivity of SSCP is

>99% for 100-300 bp fragments, however the mutated sequence must be at least 35% of the DNA mixture34,35. Other disadvantages of these molecular analyses are
that they are very cumbersome and time consuming and not very practical for
everyday clinical use. Recently immunohistochemicai (IHC) techniques have been
used in the detection of overexpressed p53 protein. Wild-type p53 has a relatively
short half-life of 5-40 minutes and its nuclear presence is usually not detectable via
immunohistochemicai procedures36. However, mutations in the p53 gene lead to
conformational changes in protein structure and increased stability of the protein
with a resultant increased half-life of many hours37. It is the p53 protein with
increased stability that is detected by IHC. Studies by Esrig et ah, have shown there
to be a good correlation between overexpression of p53 (detected by IHC) and
mutations in the p53 gene (detected by molecular genetic analysis)36. However, false
positives and false negatives still persist which can be explained by a number of
hypotheses(See discussion). IHC analysis may be more sensitive than genetic
molecular studies. IHC is able to detect protein expression on a cell to cell basis
whereas the sensitivity of molecular analysis depends upon the ratio of mutant to
wild-type DNA. IHC is also able to assess the functional status of the p53 protein.
It is the nonfunctioning protein with increased stability that is detected by IHC.
Whereas with genetic analysis there are several scenarios in which a normal gene
may be present but the protein may be nonfunctioning secondary to the cellular
environment (see below).
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P53 has been shown to form oligomeric protein complexes with a number of
viral and cellular proteins14. P53 was originally discovered as a complex bound to the
simian virus 40 (SV40) large-T antigen ’8 j4 and subsequently was found to form
complexes with human papillomavirus E640, Epstein-Barr virus nuclear antigen 541,
adenovirus type 5 Elb 55-kDa protein4", hepatitis B virus X antigen4', and
lymphotropic papovavirus large tumor antigen44. The functional status of p53 is
determined by a number of factors including its physical conformation, cellular
environment, and interactions with cellular and viral proteins14.

As discussed above,

many of the genetic mutations involving the p53 gene lead to conformational
changes in protein structure which alters the overall functional capacity and stability
of p53. Levine et al., demonstrated how different mutations in the p53 gene result
in proteins with different functional capacities45. For example, a mutated p53
protein with a substituted amino-acid residue 175 leads to loss of its transactivation
capability45. Protein stability, as measured by half-life, is also affected by cellular and
viral protein interactions. Sarnow et ah, demonstrated that p53 has a much longer
half-life when complexed with the viral proteins SV40 large T antigen and
adenovirus Elb 55kDa protein 4",4b. Conversely, binding of p53 to the human
papillomavirus types 16 and 18 E6 protein rapidly increases its rate of degradation40.
A number of independent investigators have shown p53 loses its transactivation
capability when bound to specific viral proteinsj8,j9,40’42. Based on the above findings,
IHC has proven more sensitive in the assessment of p53 function than genetic
molecular analysis.

IHC has the advantage of being able to detect accumulated

wild-type p53 whose function is altered through viral protein binding.
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Mdm2 (murine double minute-2) is a gene that encodes for a 90 kDa protein
which has the ability to bind p53 and inactivate its activity as a transcriptional
factor47. The human MDM2 gene has been localized to chromosome 12q 13-144S.
The MDM2 protein has been shown by Oliner et al., to possess the ability to bind
p53 and conceal its activation domain from cellular transcription elements41'. MDM2
was first discovered as an amplified gene on a double minute chromosome of the
spontaneously transformed mouse cell line BALB/c50. Oliner et al., also
demonstrated that MDM2 gene amplification is associated with human sarcomas of
soft tissue and bone48. On a cellular level MDM2 gene amplification and
overexpression increases the tumorigenic potential of cells51,52. Work by Wu et al.,
has shown there to be an autoregulatory feedback loop between p53 and MDM2T
They were able to show that the MDM2 gene contains a p53 DNA binding site and
that expression of this gene could be regulated by wild-type p53 A Furthermore, the
MDM2 protein is able to inhibit p53 function as described above. So, MDM2
expression is regulated by p53 at the transcriptional level while p53 activity is
regulated by MDM2 at the protein level.
The purpose of this study was to analyze the frequency of abnormalities in
p53 and MDM2 expression for superficial bladder cancer. We also hope to
determine if alterations in either may be of any clinical significance in terms of
indicators of recurrence or potential prognostic factors.
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Patimt Population
I reviewed the medical charts of patients at the Yale-New Haven Hospital
and West Haven VA who presented for transurethral resection of suspected bladder
tumors between January 1989 and January 1996. Patients were selected whose
biopsy specimens revealed superficial disease consisting of stages Ta, Tl, and Tis.
The patients clinical information was compiled consisting of age, sex, presenting
symptoms, diagnostic work up, tumor grade, stage, multifocality, presence of
carcinoma in situ, treatment received and subsequent follow up. Sections of the
paraffin embedded biopsy specimens stained with hematoxylin-eosin were reviewed
and the most representative tumor specimen was selected for sectioning and
immunohistochemistry with the appropriate antibody.

Monoclonal Antibodies and Immunohistochemical Procedures
Five micrometer sections of archival formalin-fixed, paraffin-embedded tissue
were placed on Silane coated slides and heated at approximately 60°C for one hour.
Deparaffinization was accomplished with iodine-xylene and tissue was rehydrated
with 95% ethanol. Endogenous peroxidase was quenched in 3% hydrogen
peroxide/methanol. For staining with the anti-p53 antibody, antigen retrieval was
performed with a citrate buffer (pH 6) for a total of 10 minutes (two separate 5
minute intervals) in a standard microwave unit. Tissue was then cooled and
incubated with a 5% horse serum for blocking purposes. The anti-p53 mouse
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monoclonal antibody DO-7 (DAKO-p53 Protein; dilution, 1:200, DAKO Japan,
Kyoto, Japan) was applied to tissue for overnight incubation at 4°C. The exact
binding site of the D07 antibody is currently unknown. Phosphate-buffered saline
was used to wash the tissue followed by incubation with a biotinylated horse anti¬
mouse secondary antibody at a concentration of 1:200 (Vector Labs, Burlingame,
Calif.). Visualization of reactivity with an avidin-biotin complex immunoperoxidase
system (Vector) according to the manufacturer’s recommendations was followed by
diamino-benzidine (0.03%) used as a chromogen and hematoxylin for the
counterstain. Samples of bladder carcinoma with known p53 mutations and
documented accumulation of p53 protein by immunohistochemical analysis were
used as positive controls. Normal urothelium and nonepithelial cells (lymphocytes,
stromal cells, and endothelial cells), used as internal negative controls, demonstrated
no immunoreactivity. Only nuclear localization of immunoreactivity was evaluated.
The extent of nuclear reactivity was classified in four categories. No nuclear
reactivity; a few focally positive nuclei (1 to 9 percent of tumor cells); heterogenous
nuclear reactivity (10 to 49 percent of tumor cells); and intense homogeneous nuclear
reactivity (50 to 100 percent of tumor cells) (Fig. 1). Only samples demonstrating at
least 10 percent nuclear reactivity were considered to be p53-positive (to have an
alteration in p53). Tissue samples demonstrating less than 10 percent nuclear
reactivity were considered p53 negative. This criterion was based on the
demonstration of a strong correlation of mutations in the p53 gene with the
accumulation of p53 protein in 10 percent or more of the tumor-cell nuclei^6. All
cases were independently read by two investigators (JNA, DE). The

13

immunohistochemical analysis was performed without knowledge of the tumor stage
or the results of clinical follow-up.
For the anti-mdm2 antibody, antigen retrieval consisted of a 10 mM sodium
citrate buffer (pH 6.0) heated to 95°C in a water bath for 10 minutes. Otherwise the
procedure for mdm2 staining was the same as for p53. The anti-mdm2 mouse
monoclonal antibody IF2 (IgG2b class, at concentration 5.0 ug/ml, Oncogene
Science, Uniondale, N.Y.) was applied to tissue for overnight incubation at 4°C. IF2
recognizes an epitope in the amino terminal portion of the 491 amino acid human
mdm2 protein. The OSA-cl cell line known to overexpress the mdm2 protein'4 was
used as a positive control and in determining the concentration of the anti-mdm2
antibody. Serial dilutions were used to minimize background staining and achieve
optimal nuclear staining. Normal urothelium and nonepithelial cells (lymphocytes,
stromal cells, and endothelial cells), used as internal negative controls, demonstrated
no immunoreactivity. Only nuclear localization of immunoreactivity was evaluated.
The nuclear reactivity criterion described above for the p53 staining was also used
for evaluation of mdm2 staining (Fig. 2).

Statistical Analysis
To allow for the variable length of follow up, survival analysis was employed.
Cox proportional hazards regressions were performed to assess the dependence of
failure time (time to recurrence) on p53 status, controlling for potential confounders
and exploring effect modification by mdm2 status. The rate ratio was used to
summarize the strength of association between the potential risk factors and the risk
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of a recurrent tumor. The term censored describes patients who did not have a
recurrence of their tumor or who were lost to follow up during the study. The
validity of the Cox regressions was assessed to ensure that the underlying
assumption of constant hazard rate ratios was not violated. For the purpose of the
statistical analysis, nuclear accumulations of p53 and mdm2 were classified as either
positive (accumulation in 10 percent or more of tumor cells) or negative.
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Results

Tables 1 and 2 summarize characteristics of the subjects studied and their
incident bladder tumors. The study consisted of 84 patients and 85 incident bladder
tumors with one subject presenting with two distinct tumors. The mean age of the
subjects was 72.9 (range 43 to 90) years. 78 (93%) of the subjects were male and 6
(7%) were female. 35 (42%) were patients from the Veterans Hospital and 49 (58%)
were from Yale-New Haven Hospital. Of the 85 bladder tumors 8 (9%) were
classified histologically as grade 1, 43 (51%) as grade 2, 31(36%) as grade 3, and 3
(4%) as grade 4. 54 (64%) of the tumor specimens were a pathologic stage Pa
(confined to the mucosa), 23 (27%) were PI (superficial lamina propria invasion), and
7 (8%) were Pis (carcinoma in situ). 16 (19%) of the subjects had biopsy proven
carcinoma in situ. Of the 84 patients, 28 (33%) received some form of intravesical
chemotherapy. Secondary to incomplete charts or inadequate tissue specimens, data
was missing for stage (n=l), p53 status (n=8), and mdm2 status (n=18). As a result of
this missing data our sample size analyzed included 66 patients and 66 tumors. The
sample size analyzed was a subset of the total sample population and did not possess
any significant different characteristics from the total sample population. Of the 66
subjects analyzed, 41 (62%) were positive for overexpression of the p53 protein. 8
(12%) of the 66 subjects were positive for overexpression of the mdm2 protein. 40
(61%) of the 66 patients analyzed had a recurrence of their tumor. The mean

1

16

number of months until last follow up for censored patients was 23.4 (range 0 to 62)
while the mean number of months until recurrence was 9.23 (range 1 to 40).
Tables 3 through 5 summarize the effect of modeling mdm2 in multivariate
models with p53. A multivariate model was constructed to examine the effect of
different variables on the rate of recurrence for superficial bladder cancer. The
model included all variables which in and of themselves contributed significantly to
predicting bladder cancer recurrence and any variable which influenced p53’s ability
to predict bladder cancer recurrence (a confounder). Variables predictive of bladder
cancer recurrence were selected based on significant p-values (<.05). Variables
influencing p53’s ability to predict bladder cancer recurrence (confounders) were
selected based on their ability to cause at least a 10 percent change in the parameter
estimate which the rate ratio is based upon. The confounders and variables
predictive of bladder cancer recurrence included stage, presence of CIS (carcinoma
in situ) and whether or not chemotherapy was initiated. Table 3 models the effect of
p53 and confounding variables on the rate of bladder cancer recurrence. Table 4
models the effect of p53 on the rate of bladder cancer recurrence controlling for
mdm2 as a confounding variable. Table 5 models the effect of p53 on the rate of
bladder cancer recurrence assessing for an effect modification of p53 by mdm2 and
takes into account the status of mdm2 (positive versus negative). Table 3 states that
the rate of recurrence for bladder tumors that were p53 positive is 2.70 times that of
tumors that were p53 negative. The 95% confidence intervals were from 1.10 to 6.61
with a significant p-value of 0.03. These values controlled for stage, presence of CIS,
and chemotherapy. Table 3 also modeled the effect of stage, presence of CIS, and
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chemotherapy on the rates of recurrence. Pathological stage Pis had a rate of
recurrence 6.04 times that of pathological stage Pa.

The 95% confidence intervals

were from 1.13 to 32.45 with a p-value of 0.04. The presence of CIS had a rate of
recurrence 4.89 times that of tumors with no evidence of CIS. The 95% confidence
intervals were from 1.35 to 17.68 with a p-value of 0.02. Having received intravesical
chemotherapy correlated with a rate of recurrence 0.32 times that of patients that did
not receive chemotherapy. The 95% confidence intervals were from 0.10 to 1.07
with a borderline significant p-value of 0.07. Having received chemotherapy was one
of the variables that when removed from our model it significantly effected the
predictive value of p53 in tumor recurrence. The Likelihood Ratio (LR) Chi-square
test was used to assess if the model as a whole was significant. The LR Chi-square
was 14.39 with 5 degrees of freedom and a p-value of 0.01 for our model of p53 alone
in table 3. The LR test of significance was also used to assess significance of the
model as a whole and was 5.4 with 1 degree of freedom and a p-value of 0.02 for the
model of p53 alone in table 3.
Table 4 models the same variables as in table 3 with the addition of mdm2 as
a confounding factor. The rate ratio of bladder tumor recurrence for p53 positive
tumors was 2.62 times that of p53 negative tumors with 95% confidence intervals of
1.06 to 6.49 and a p-value of 0.04. These values controlled for stage, presence of
CIS, chemotherapy and mdm2 as confounding factors. Mdm2 positive tumors did
not have a significantly increased rate ratio for tumor recurrence when compared to
mdm2 negative tumors. The rate ratio was 1.52 with 95% confidence intervals
between 0.56 and 4.08 and a p-value of 0.41. With mdm2 included as a confounding
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factor, bladder tumors that were positive for p53 and negative for mdm2 had a rate
ratio for tumor recurrence that was 2.62 times that of the reference group (p53
negative, mdm2 negative) with 95% confidence intervals from 1.06 to 6.49 and a pvalue of 0.04. Tumors that were positive for p53 and positive for mdm2 had a rate
ratio for tumor recurrence that was 3.97 times that of the reference group with 95%
confidence intervals from 1.11 to 14.29 and a p-value of 0.03. Table 4 also modeled
the effect of stage, presence of CIS, and chemotherapy on the rates of recurrence.
Pathological stage Pis had a rate of recurrence 6.27 times that of pathological stage
Pa. The 95% confidence intervals were from 1.16 to 33.99 with a p-value of 0.03.
The presence of CIS had a rate of recurrence 5.30 times that of tumors with no
evidence of CIS. The 95% confidence intervals were from 1.43 to 19.62 with a pvalue of 0.01. Having received intravesical chemotherapy correlated with a rate of
recurrence 0.30 times that of patients that did not receive chemotherapy. The 95%
confidence intervals were from 0.09 to 1.00 with a p-value of 0.05. The LR Chisquare was 15.02 with 6 degrees of freedom and a p-value of 0.02 for our model of
p53 and mdm2 in table 4. The LR test of significance was also used to assess
significance of the model as a whole and was 6.02 with 2 degrees of freedom and a
p-value of 0.05 for the model of p53 and mdm2 in table 4. The LR test of
significance was used to assess if the current model added any significant
information regarding the rates of recurrence when compared to the previous model.
Compared to the previous model of p53 alone, the LR Chi-square was 0.62 with one
degree of freedom and a nonsignificant p-value of 0.431. This demonstrates that our
model with the addition of mdm2 as a confounding factor added no significant
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information regarding the rates of recurrence when compared to our model of p53
alone.
Table 5 models the effect of p53 on the rate of bladder cancer recurrence
assessing for an affect modification of p53 by mdm2. The rate ratio of tumor
recurrence for p53 positive subjects was 3.25 times that for p53 negative subjects
when mdm2 was negative. The 95% confidence intervals were from 1.25 to 8.47
with a p-value of 0.02. The rate ratio of tumor recurrence for p53 positive subjects
was 0.20 times that for p53 negative subjects when mdm2 was positive. The 95%
confidence intervals were from 0.02 to 2.11 with a non-significant p-value of 0.18.
The rate ratio of tumor recurrence for mdm2 positive subjects was 20.02 times that
for mdm2 negative subjects when p53 was negative. The 95% confidence intervals
were from 1.81 to 221.72 with a p-value of 0.01. The rate ratio of tumor recurrence
for mdm2 positive subjects was 1.23 times that for mdm2 negative subjects when
p53 was positive. The 95% confidence intervals were from 0.42 to 3.63 with a non¬
significant p-value of 0.70. Bladder tumors that were negative for p53 and positive
for mdm2 had a rate ratio for tumor recurrence that was 20.02 times that of the
reference group (p53 negative, mdm2 negative) with 95% confidence intervals from
1.81 to 221.72 and a p-value of 0.01. Tumors that were positive for p53 and negative
for mdm2 had a rate ratio for tumor recurrence that was 3.25 times that of the
reference group with 95% confidence intervals from 1.25 to 8.47 and a p-value of
0.02. Tumors that were positive for p53 and positive for mdm2 had a rate ratio for
tumor recurrence that was 4.00 times that of the reference group with 95%
confidence intervals from 1.01 to 15.94 and a p-value of 0.05. Table 5 also modeled
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the effect of stage, presence of CIS, and chemotherapy on the rates of recurrence.
Pathological stage Pis had a rate of recurrence 6.73 times that of pathological stage
Pa. The 95% confidence intervals were from 1.19 to 38.23 with a p-value of 0.03.
The presence of CIS had a rate of recurrence 6.97 times that of tumors with no
evidence of CIS. The 95% confidence intervals were from 1.77 to 27.40 with a pvalue of 0.01. Having received intravesical chemotherapy correlated with a rate of
recurrence 0.26 times that of patients that did not receive chemotherapy. The 95%
confidence intervals were from 0.07 to 0.94 with a p-value of 0.04. The LR Chisquare was 18.15 with 7 degrees of freedom and a p-value of 0.01 for our model of
p53, mdm2 and their interaction in table 5. The LR test of significance was also
used to assess significance of the model as a whole and was 9.15 with 3 degrees of
freedom and a p-value of 0.03 for the model of p53, mdm2, and their interaction in
table 5. The LR test of significance was used to assess if the current model added
any significant information regarding the rates of recurrence when compared to the
previous model. Compared to the previous model of p53 and mdm2, the LR Chisquare was 3.14 with one degree of freedom and a significant Wald p-value of 0.03.
This demonstrates that our model with the addition of mdm2 assessing for an
interaction with p53 did add significant information regarding the rates of recurrence
when compared to our previous model of p53 and mdm2.
Table 6 summarizes the protective effect of negative p53 and negative mdm2
versus all other combinations. Column 1 (p53, mdm2, and interaction) is described
in table 5. Column 2 (contrast) combines all tumor marker combinations (p53mdm2+; p53+ mdm2 -; p53+ mdm2+) and compares them to the reference group of
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p53 negative, mdm2 negative. Any aberration in the tumor markers p53 and mdm2
have a rate ratio of tumor recurrence 3.31 times that of the reference group (p53
negative, mdm2 negative) with 95% confidence intervals from 1.29 to 8.49 and a pvalue of 0.01. As in all previous models, column 2 also modeled the effect of stage,
presence of CIS, and chemotherapy on the rates of recurrence. Pathological stage Pis
had a rate of recurrence 6.77 times that of pathological stage Pa. The 95%
confidence intervals were from 1.22 to 37.65 with a p-value of 0.03. The presence of
CIS had a rate of recurrence 5.73 times that of tumors with no evidence of CIS. The
95% confidence intervals were from 1.57 to 20.92 with a p-value of 0.01. Having
received intravesical chemotherapy correlated with a rate of recurrence 0.30 times
that of patients that did not receive chemotherapy. The 95% confidence intervals
were from 0.09 to 1.02 with a p-value of 0.05. The LR Chi-square was 16.30 with 5
degrees of freedom and a p-value of 0.01 for our model of contrast in column 2. The
LR test of significance was also used to assess significance of the model as a whole
and was 7.30 with 1 degree of freedom and a p-value of <0.01 for the model of
contrast in column 2.
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Table 1: Characteristics of the study subjects and incident
primary superficial bladder tumors.

Sample Analyzed

Total Sample

known p53, mdm2, followup
months

Study Subjects
Age at incidence

84 patients, 85 tumors

66 patients, 66 tumors

Mean 72.9
Q: 43,67.5,73,78,90

Mean 72.6
Q: 43,68,73,78,90

n

%

n

%

male
female

78
6

93
7

61
5

92
8

VA
YNHH

35
49

42
58

31
35

47
53

G2
G3
G4

8
43
31
3

9
51
36
4

6
35
22
3

9
53
33
5

Stage*

Ta
T1
Tis

54
23
7

64
27
8

43
19
4

65
29
6

CIS

positive
negative

16

19
81

11
55

17
83

Sex

Hospital

Primary Tumor
Characteristics
Grade
G1

69

* Data were missing for Stage (n=l), p53 status (n=8), and mdm2 status (n=18).
Q: represents minimum, first quartile, median, third quartile and maximum value.
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Table 2: Therapy and tumor marker status of incident primary
superficial bladder tumors.

Sample Analyzed

Total Sample

known p53, mdm2.
followup months
84 patients, 85 tumors

66 patients, 66 tumors

n

%

n

%

no

57

67

41

62

yes

28

33

25

38

44

57

41

62

33

43

25

38

Chemotherapy initiated

p53*
positive
negative

8

12

8

12

59

88

58

88

Censored

34

40

26

39

Recurred

50

60

40

61

mdm2*
positive
negative
Recurrences

Months to last
f/u if cens.

Mean 22.6

Mean 23.4

Q: 0,6,22,32,62

Q: 0,6,24,32,62

Months to

Mean 9.26

Mean 9.23

recurrence

Q: 1,4,6.5,11,40

Q: 1,3.5,6.5,11,40

# Data were missing for Stage (n=l), p53 status (n=8), and mdm2 status (n=18).
Q: represents minimum, first quartile, median, third quartile and maximum value.
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Table 3: The effect of p53 and confounding variables on the rate of
bladder cancer recurrence for sample analyzed
p53 only
Wald
RR

Tumor markers:
pm

vs pm

If mdm2 (-)

+ -

vs - -

If mdm2 ( + )

+ +

vs - +

P53

2.7

(+) vs. (-)

95% Cl

(1.10, 6.61)

p-value

0.03 s

mdm2
(+) vs. (-)
If p53 (-)

- +

If p53 (+)

+ +
p53

vs - vs + mdm2

-

24

-

-

+

34

+

-

7

+

+

1

Control variables:
Ta

Stage

CIS

1

Ref
0.4

T1

1.59

(0.54, 4.68)

TIS

6.04

(1.13, 32.45)

0.04 s

4.89

(1.35, 17.68)

0.02 s

0.32

(0.10, 1.07)

0.07 b

yes vs. no

Chemotherapy

yes vs. no

LR
Significance tests:
Model: LR Chi-square, df, p -value

df

p-value

14.39

5df

0.01 s

5.4

1 df

0.020 s

Chi-square

LR test of significance:
Of tumor markers
vs previous model

b=borderline significant at .10 level (<.10,>=.05); s=significant at .05 level (<.05,>=.01);
h=highly significant at .01 level (<.01); p=p53, m=mdm2, RR=rate ratio, df=degrees of
freedom, CI=confidence intervals, (-)=negative, (+)=positive
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Table 4: The effect of p53 on the rate of bladder cancer recurrence
controlling for mdm2 as a confounding variable for sample analyzed.
p53 and mdm2
Wald
RR

Tumor markers:
pm

p53
(+)

VS.

95% Cl

p-value

vs pm

(-)
If mdm2 (-)

+-

vs - -

If mdin2 ( + )

+ +

vs - +

If p53 <-)

- +

vs - -

If P53 (+)

+ +

2.62

(1.06, 6.49)

0.04 s

1.52

(0.56, 4.08)

0.41

mdm2
( + ) vs. (-)

p53
24

-

vs + mdm2
-

1

Ref

1

-

+

1.52

(0.56, 4.08)

0.41

34

+

-

2.62

(1.06, 6.49)

0.04 s

7

+

+

3.97

(1.11, 14.29)

0.03 s

Control variables:
Stage

Ta

CIS

T1

1.66

(0.56, 4.90)

TIS

6.27

(1.16, 33.99)

0.03 s

5.3

(1.43, 19.62)

0.01 s

0.3

(0.09, 1.00)

0.05 b

yes vs. no

Chemotherapy

yes vs. no

0.36

LR
Significance tests:

Chi-square

df

p-value

15.02

6df

0.02 s

Of tumor markers

6.02

2df

0.049 s

vs previous model

0.62

ldf

0.431

Model: LR Chi-square, df, p -value
LR test of significance:

b=borderline significant at .10 level (<.10,>=.05); s=significant at .05 level (<.05,>=.01);
h=highly significant at .01 level (<.01); p=p53, m=mdm2, RR=rate ratio, df=degrees of
freedom, CI=confidence intervals, (-)=negative, ( + )=positive
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Table 5: The effect of p53 on the rate of bladder cancer recurrence
assessing for an affect modification of p53 by mdm2 for sample
analyzed.
p53, mdm2 and interaction
Wald
Tumor markers:

RR

95% Cl

p-value

pm vs pm

p53
( + ) VS. (-)

If mdm2 (-)

+- vs —

3.25

(1.25, 8.47)

0.02 s

If mdm2 ( + )

++ vs-+

0.2

(0.02, 2.11)

0.18

If p53 (-)

-+ vs —

20.02

If P53 ( + )

++ vs +-

1.23

mdm2
( + ) vs. (-)

p53

1

1

+
+

7

+

(0.42, 3.63)

0.01 s
0.7

mdm2

24
34

(1.81, 221.72)

+

Ref

20.02

(1.81, 221.72)

0.01 s

3.25

(1.25, 8.47)

0.02 s

(1.01, 15.94)

0.05 s

4

Control variables:
Stage

CIS

Ta
T1

1.61

(0.51, 5.07)

TIS

6.73

(1.19, 38.23)

0.03 s

6.97

(1.77, 27.40)

0.01 h

0.26

(0.07, 0.94)

0.04 s

yes vs. no

Chemotherapy yes vs. no

0.41

LR
Significance tests:

df

p-value

18.15

7df

0.01 s

Of tumor markers

9.15

3df

0.03 s

vs previous model

3.14

ldf

0.03 s

Model: LR Chi-square, df, p-value

Chi-square

LR test of significance:

b=borderline significant at .10 level (<.10,>=.05); s=significant at .05 level (<.05,>=.01);
h=highly significant at .01 level (<.01);p=p53, m=mdm2, RR=rate ratio, df=degrees of freedom,
CI=confidence intervals, (-)=negative, ( + )=positive
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Table 6: Modelling a contrast : the protective effect of (-) p53 and (-) mdm2 vs. all

b=borderline significance at .10 level (<.10, >=.05); s=significant at .05 level (<.05, >=.01); h=highly significant at
.01 level; p=p53, m=mdm2, RR=rate ratio, df=degrees of freedom, CI=confidence intervals, (-)=negative,
(+)=positive
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Figure 1. Immunohistochemical detection of p53 protein in the nuclei of
transitional-cell carcinomas of the bladder with the anti-p53 monoclonal
antibody D07. Panel A: No detectable nuclear staining seen.
Panel B: Heterogeneous nuclear reactivity is seen in 10 to 49 percent of
tumor cells (straight arrow indicates no nuclear staining,curved arrow
indicates positively stained nuclei). Panel C: Intense homogeneous
nuclear reactivity is seen in 50 to 100 percent of tumor cells (all panels x200).
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Figure 2. Immunohistochemical detection of MDM2 protein in the nuclei of
transitional-cell carcinomas of the bladder with the anti-MDM2 monoclonal
antibody IF2. Panel A: No detectable nuclear staining seen.
Panel B: Heterogeneous nuclear reactivity is seen in 10 to 49 percent
of tumor cells (straight arrow indicates no nuclear staining,curved arrow
indicates positively stained nuclei). Panel C: Intense homogeneous
nuclear reactivity is seen in 50 to 100 percent of tumor cells (all panels x200).
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We proposed to analyze the expression of two tumor markers, p53 and mdm2,
in patients with superficial bladder cancer. We sought to determine if alterations in
the expression of these genes are of any clinical significance in terms of predicting
recurrence of bladder tumors. 41 (62%) of the 66 superficial tumors analyzed were
positive for overexpression of the p53 protein. 8 (12%) of the 66 superficial tumors
analyzed were positive for overexpression of the mdm2 protein. Previous studies of
p53 expression in superficial tumors utilizing immunohistochemical (IHC)
techniques have not yielded such a high percentage of p53 positive tumors. A study
by Esrig et al., found 22% of superficial bladder tumors (Pa, Pis and PI) to be
positive for overexpression of the p53 protein'4. A previous study by Esrig et al.,
found 33% of superficial tumors (Pa and PI) to be positive for overexpression of the
p53 protein’6. Lipponen found 25% of superficial tumors (Pa and PI) to be positive
for overexpression of the p53 protein33. A number of explanations can account for
our higher percentage of p53 positive superficial tumors. Immunohistochemical
findings have already been shown to have a high correlation with molecular studies
such as direct sequencing of PCR amplified DNA fragments and single strand
conformational polymorphism analysis (SSCP)36. Previous studies have shown
overexpression of p53 protein in IHC to be highly specific (90%) for mutations in the
p53 gene60. However, false positives and false negatives still persist. False positives
refer to cases in which there was overexpression of p53 protein via IHC analysis but
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no detectable abnormality in the p53 gene via molecular genetic analysis. False
positives may result from the increased expression of wild-type (no genetic
abnormalities) p53 protein. Barnes et al., described an alteration in the promoter
region of a normal p53 gene which lead to the overexpression of wild-type protein in
a family with breast cancer syndrome61. Exposure of cells to DNA damaging
elements such as UV light, gamma irradiation and chemotherapeutic agents also
results in an increase in the cellular levels of wild-type p53-8'-9. P53 has been shown
to form oligomeric protein complexes with a number of viral and cellular proteins19.
Stabilization of the wild-type protein through complex formation with viral and
cellular proteins can result in nuclear accumulation of p53 protein and subsequent
false positive detection via IHC techniques. An important question to consider in
these studies is how does stabilization of the p53 protein through complex formation
with cellular and viral proteins effect the overall function of the p53 protein. A
number of independent investigators have shown that p53 loses its transactivation
capability when bound to specific viral proteinsj8’j9’40'4“. False positives may also be
the result of inadequate molecular analysis of the p53 gene. The majority of
mutations involving the p53 gene are found within exons 5-8 (evolutionarily highly
conserved regions) and as a result these regions are the ones analyzed for genetic
mutations. However, it is feasible that alterations found via IHC are actually the
result of genetic mutations outside of the evolutionarily conserved domains. Lastly,
false positives may be due to the insensitive nature of genetic molecular analysis.
The sensitivity of genetic molecular analysis depends upon the ratio of genetically
mutated DNA to that of normal wild-type DNA. Therefore if the tissue under
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analysis has a low ratio of tumorgenic to normal tissue, molecular genetic methods
may yield falsely negative results. Sidransky et al., have shown that when the ratio
of cells containing mutations is low molecular methods are unable to detect such
mutations62.
False negatives refer to cases in which there was no detectable
overexpression of p53 protein via IHC analysis, however, molecular genetic analysis
revealed mutations in the p53 gene. False negatives may be the result of specific
types of mutations in the p53 gene. For example, a point mutation may code for a
stop codon and truncate the protein product making nuclear accumulation and IHC
detection impossible. Codon 196 codes for the nuclear localization domain of the
protein which is at amino acids 316-32520. Mutations that involve the nuclear
localization domain of the gene may inhibit the ability of p53 protein to enter the
nucleus and thus effect its detection by IHC methods. Certain gross deletions may
result in eradication of any p53 protein48. Wild-type p53 protein has a relatively short
half-life of 5 to 40 minutes06. Detection of alterations in the p53 gene by IHC is
based on the premise that the majority of mutations involving the p53 gene result in
a conformational change of protein structure and subsequent stabilization of the
protein. The stabilized protein has an increased half-life of several hours07. False
negatives may be the result of missense point mutations that do not result in a
protein with increased stability and half-life60. As discussed above, there are a
number of viral and cellular proteins that form complexes with the p53 protein.
False negatives may be the result of a complex formation that conceals the binding
site (epitope) of the antibody being used in IHC. In a similar fashion, genetic
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mutations involving epitopes for particular antibodies may effect their ability to
detect accumulated p53 protein via IHC. For example a mutation in exon 5 of the
p53 gene may lead to a conformational change in the corresponding portion of the
p53 protein. As a result, antibodies that are specific for that portion of the protein
will no longer effectively recognize the mutated epitope.
Results of IHC are extremely dependent upon the technical conditions under
which they are performed. Factors such as the primary antibody, antigen retrieval
methods, and fixatives used in the processing of tissues can all effect the results of
IHC. In our study, staining for overexpression of the p53 protein was done with the
mouse monoclonal antibody D07. Most previous studies evaluating overexpression
of p53 protein used the mouse monoclonal antibody PAbl801. Data implicating
D07 as a much more sensitive antibody in the detection of overexpressed p53
protein may explain our findings of an increased percentage of superficial tumors
positive for p53. Baas et al., undertook a study evaluating six antibodies for IHC
detection of p53 in archival colorectal neoplasms60. The p53 gene mutational status
of all tumors was previously determined through polymerase chain reaction and
double-stranded DNA sequencing of the products. Both of the antibodies D07 and
1801 were included in this study. Baas et al., found that of the six antibodies
studied, D07 in combination with Target Unmasking Fluid (TUF) used for antigen
retrieval was the most sensitive and specific in immunostaining of p5360.
Antigen retrieval methods also appear to affect the results of IHC. Our study
utilized an antigen retrieval method similar to that of the TUF method. We
incubated tissues in a citrate buffer for a total of ten minutes in a standard microwave

34

unit. The TUF method consists of immersing the tissue in a solution and heating
for ten minutes at 90°C in a temperature probe-controlled microwave oven. Prior
studies of Esrig et ah, and Lipponen which determined expression of p53 in
superficial tumors had not utilized any method of antigen retrievaP6,54'55. Our use of
the most sensitive and specific antibody available coupled with antigen retrieval
methods can explain our findings of superficial tumors with a higher percentage of
positive staining for p53.
In our study, we found there to be an increased risk of recurrence with
superficial bladder cancer for patients who had any aberration in the status of their
tumor markers, p53 and mdm2. Consistent with the literature, we found that the
presence of CIS had an increased risk of recurrence4. Also consistent with the
literature, we found that alterations in the tumor marker p53 had an increased risk of
recurrence54. New findings in our study indicate that alterations in the tumor marker
mdm2 may aid in the ability of p53 to predict bladder cancer recurrence. This is
described in our model of p53, mdm2, and their interaction. Mdm2 is a cellular
protein which has the capability of binding and inactivating wild-type p5346. A
scenario could exist in which there is normal expression of p53 however its function
may be altered due to binding with mdm2. One can also describe a scenario in
which expression of p53 and mdm2 are both altered. If binding of p53 by mdm2
leads to a stable complex formation one would expect that overexpression of both
would be detected by IHC methods. It is the stable protein complex formation of
p53 ( with an increased half-life) that determines its overexpression detected by
IHC. For the one subject that was p53 negative and mdm2 positive we found there
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to be a high risk of recurrence. This correlates with our proposed hypothesis that
mdm2 may be functioning to inactivate wild-type p53. However, this data should be
interpreted cautiously because it is based only upon one subject. We found that
mdm2 as a tumor marker significantly added to our model of p53 and its ability to
predict bladder cancer recurrence. This was demonstrated through the likelihood
ratio test of significance of our tumor markers. When examining both tumor markers
p53 and mdm2 we found that any abnormality in their expression correlated with an
increased risk of recurrence that was 3.31 times that of normal tumor marker
expression.
Our findings have significant clinical implications. The ability to predict
which superficial tumors are more likely to recur and progress will have an enormous
impact on therapeutic options. This study may have implications in the surgical
treatment of superficially invasive disease. For example, patients having
superficially invasive disease and alterations in either of the tumor markers, p53
and/or mdm2, might consider more aggressive treatment options, such as cystectomy,
based on the findings that they are more likely to recur, progress and possibly die of
their disease. Conversely, patients with normal expression of tumor markers and
locally advanced disease might consider more conservative measures of treatment
based on the lower likelihood of disease recurrence and progression. Such
conservative measures might include systemic chemotherapy and radiation
treatment or partial cystectomy and subsequent intravesical chemotherapy. P53
status also has implications on current chemotherapeutic options. As stated earlier,
p53 is thought to be involved in apoptosis. As a result p53 negative tumors (wild-
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type) are thought to be more sensitive to chemotherapy because the pathway to
programmed cell death remains intact.
This study suffered from a relatively small patient pool. Future studies may
wish to address the same questions posed here but in a larger patient population.
IHC has allowed for the practical evaluation of genomic alterations involved in
tumorgenisis. However, future areas of study may wish to focus on the development
of a test that could assess the function of molecules involved in tumorigenesis like
p53 and mdm2.
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